New York, New York 10029

  • Alcoholism


This study is a double-blind, placebo-controlled outpatient trial to improve, through the addition of sertraline (Zoloft), the abstinence and relapse rates in alcohol- dependent individuals currently taking naltrexone (Revia).


Inclusion Criteria: - Meets the criteria for alcohol dependence. - Abstinent from alcohol for a period of at least 5 days and not greater than 30 days. - Able to read English and complete study evaluations. - A stable residence and a telephone to ensure that subjects can be located during the study. Exclusion Criteria: - Currently meets criteria for substance abuse or dependence with the exception of nicotine dependence. - Current use of disulfiram (Antabuse) or a MAO Inhibitor. - Psychotic or otherwise severely psychiatrically disabled (i.e., depressed, suicidal, current mania). - Major depression at the time of assessment. - Previous treatment with naltrexone (Revia) for alcohol dependence. - Significant underlying medical conditions such as cerebral, renal, thyroid, or cardiac disease. - Abstinent longer than 30 days prior to admission to program. - Hepatocellular disease or elevated bilirubin levels. - Females who are pregnant, nursing, or not using a reliable method of birth control.



Primary Contact:


Backup Contact:


Location Contact:

New York, New York 10029
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 20, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.